Last reviewed · How we verify

Influenza Vaccine GSK1247446A

GlaxoSmithKline · Phase 2 active Biologic

Influenza Vaccine GSK1247446A is a Biologic drug developed by GlaxoSmithKline. It is currently in Phase 2 development.

At a glance

Generic nameInfluenza Vaccine GSK1247446A
SponsorGlaxoSmithKline
ModalityBiologic
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Influenza Vaccine GSK1247446A

What is Influenza Vaccine GSK1247446A?

Influenza Vaccine GSK1247446A is a Biologic drug developed by GlaxoSmithKline.

Who makes Influenza Vaccine GSK1247446A?

Influenza Vaccine GSK1247446A is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

What development phase is Influenza Vaccine GSK1247446A in?

Influenza Vaccine GSK1247446A is in Phase 2.

Related